No Data
No Data
H.C. Wainwright Maintains Ikena Oncology(IKNA.US) With Buy Rating, Maintains Target Price $4
Buy Rating for Ikena Oncology Driven by Promising IK-595 Developments
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 Loss per Share (Vs US$0.40 Loss in 3Q 2023)
Ikena Oncology Reports Strategic Realignment and Financial Performance
Ikena Oncology GAAP EPS of -$0.21 Beats by $0.06
Ikena Oncology 3Q Loss $10.2M >IKNA